First study of CX-2051 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has spread or cannot be removed with surgery, and it has gotten worse after standard treatment.
- You are able to do most daily activities (performance status 0 or 1).
- Your tumor can be measured on a scan (like a CT scan).
- You are willing to have a fresh biopsy of your tumor, or you have a tissue sample from within the last 6 months.
- You have not had a different type of cancer (other than skin cancer or a few others) in the last 2 years.
- You have not had an antibody-drug conjugate (ADC) that contains a topoisomerase I inhibitor (like irinotecan) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.